No progress has been made on the discussions on the ALK inhibitor anticancer drug ‘Lorviqua,’ which the company had reapplied for first-line reimbursement benefits immediately upon failing to successfully conclude its first drug pricing negotiations.

According to industry sources, the health authorities have not decided at what stage they will initiate the process for Pfizer Korea’s ALK-positive NSCLC drug Lorviqua (lorlatinib), for which the company has now terminated the risk-sharing agreement (RSA) and applied to list it through the general reimbursement listing process.

It has already been more than 4 months since Pfizer submitted the application for the drug’s general reimbursem